SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-22-113145
Filing Date
2022-04-21
Accepted
2022-04-21 17:01:36
Documents
9
Period of Report
2022-06-09

Document Format Files

Seq Description Document Type Size
1 DEF 14A d279615ddef14a.htm DEF 14A 651725
2 GRAPHIC g279615g00a03.jpg GRAPHIC 132933
3 GRAPHIC g279615g00a04.jpg GRAPHIC 54558
4 GRAPHIC g279615g00g08.jpg GRAPHIC 100316
5 GRAPHIC g279615g00m51.jpg GRAPHIC 299776
6 GRAPHIC g279615g00m52.jpg GRAPHIC 205927
7 GRAPHIC g279615g40b71.jpg GRAPHIC 6303
8 GRAPHIC g279615g57t15.jpg GRAPHIC 27674
9 GRAPHIC g279615g88b19.jpg GRAPHIC 10691
  Complete submission text file 0001193125-22-113145.txt   1800138
Mailing Address 430 EAST 29TH STREET NEW YORK NY 10016
Business Address 430 EAST 29TH STREET NEW YORK NY 10016 212-923-3344
Intra-Cellular Therapies, Inc. (Filer) CIK: 0001567514 (see all company filings)

IRS No.: 364742850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36274 | Film No.: 22842176
SIC: 2834 Pharmaceutical Preparations